Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Pharma in Focus Jobs
Latest News
Alexion plans to beef up Aust portfolio
Alexion is expanding its Australian portfolio with plans to submit two new rare disease drugs for registration in early 2016.
Health atlas shows how we use meds
A new Australian Atlas of Healthcare Variation shows high variations in the use of antimicrobials, mental health and psychotropic medicines, opioids and medicines for chronic diseases such as asthma, COPD and Alzheimer's.
Pfizer lists Inlyta after long delay
Despite the Department of Health saying in September that Pfizer had decided not to proceed with listing its cancer drug Inlyta, the new drug will PBS list on December 1.
Seqirus's Fluad flu vax wins US nod
CSL's new vaccines division Seqirus has announced that the US FDA has approved Fluad, with Australia a part of a planned rollout of a new four-strain formulation of the vaccine.
'Super Pharmacies' up for tender in Vic
24/7 'Super Pharmacies' with nurses on staff plus pharmacists who deliver vaccinations and manage patients with chronic diseases are open for tender in Victoria.
Health refers Alexion's Soliris to experts
As the anniversary of the PBS listing of Alexion's Soliris approaches, the Department of Health is setting up an expert reference group to review applications from patients to continue or reinitiate treatment.
Pfizer backs doctors' rule on Inflectra
Pfizer is looking forward to the listing next Tuesday of infliximab biosimilar Inflectra, but is emphasising respect for 'the integrity of the doctor- patient relationship'.
Guild worried over location review panel
The Pharmacy Guild has expressed concern about potential bias among Health Minister Sussan Ley's appointees to the review of pharmacy location rules but says it will will work constructively with the panel.
Asthma meds to cost PBS $1.7bn
Asthma management drugs are predicted to cost the government $1.7 billion over the next four years with the bill for 2019 alone forecast to hit $445 million.
Chem Warehouse cops on-line fine
Epharmacy Group, which owns the Chemist Warehouse website, has been fined for false or misleading representations of consumer savings.
Open Forum
Time to get subjective about drugs
The highly objective approach to determining the effectiveness of drugs embodied in clinical trials comes under question from an Australian doctor and mathematician who says it may rule out useful treatments unnecessarily.
Pipeline Monitor
Regulators in a generous mood
The FDA and the EMA have been busy approving and recommending new cancer, HIV and heart failure drugs.
Working Life
Staff rate managers in industry survey
Managers in Australian pharma companies have been given a positive report card from staff in the latest industry survey, although there are significant differences between branded only, generic only and combination companies.
Approvals Action
First competitor for narcolepsy drug
The first generic competitor for Teva'smulti-million dollar narcolepsy drug Modavigil has arrived on the PBS along with a raft of additions to already listed generics.
Special Report
Aussie pharma: flat-footed in the face of change?
A heavy compliance burden, regular downsizing and senior management churn are conspiring to leave Aussie pharma flat-footed when confronted by the challenges that a year such as 2016 is expected to bring, industry insiders fear.
FREE Content
Events & Conferences
Pharma in Focus Jobs
Eye for Pharma